Komori
Share Issuance and Disposal4889Renascience Inc.Pharmaceuticals

Notice Regarding Completion of Payment for New Shares and Stock Acquisition Rights Issued Through the Fourth Third-Party Allotment Under the Agreement Establishing the Share and Stock Acquisition Rights Issuance Program, and Withdrawal of the Shelf Registration

For the fourth third-party allotment, payment for 263,400 new shares and the allotment of 1,712 stock acquisition rights have been completed. The shelf registration was also withdrawn because all issuances under the program have been completed.

Worth reading
72In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
522849000
Yen (funds raised from the new shares; total funds raised including the stock acquisition rights: ¥866,089,592)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares and stock acquisition rights through a third-party allotment

発行・処分する株式数

New shares 263,400 shares / Potential shares underlying the stock acquisition rights 171,200 shares (1,712 rights, each convertible into 100 shares)

Intended allottee
Name CVI Investments, Inc. / Number of shares 263,400 shares, Name CVI Investments, Inc. / Stock Acquisition Rights 1,712 rights
New shares ¥1,985 per share / Stock Acquisition Rights ¥1,991 per right
Total issue value

New shares ¥522,849,000 / Stock Acquisition Rights ¥3,408,592

Amount of funds to be raised
New shares ¥522,849,000 / Stock Acquisition Rights ¥343,240,592 (¥3,408,592 from the issuance of the stock acquisition rights and ¥339,832,000 from their exercise) / Estimated net proceeds Not disclosed
Terms of the stock acquisition rights
Exercise price
¥1,985 per share. Whether there is an adjustment clause and the adjustment floor: Not disclosed
Exercise period
27 March 2026 to 26 September 2029
Number of Stock Acquisition Rights
Total issued: 1,712 rights. Unexercised balance: Not disclosed
Payment date
26 March 2026
Most recent equity financing
Timing Offering results under the shelf registration disclosed on 28 November 2025 / Type These common shares / Amount ¥1,891,228,800, Timing Offering results under the shelf registration disclosed on 28 November 2025 / Type Issue price of these stock acquisition rights / Amount ¥12,591,515, Timing Offering results under the shelf registration disclosed on 28 November 2025 / Type Aggregate of the issue price of these stock acquisition rights and the amount payable upon their exercise / Amount ¥1,256,042,515
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares and stock acquisition rights through a third-party allotment
Number of shares to be issued or disposed ofNew shares 263,400 shares / Potential shares underlying the stock acquisition rights 171,200 shares (1,712 rights, each convertible into 100 shares)
Issue price and disposal priceNew shares ¥1,985 per share / Stock Acquisition Rights ¥1,991 per right
Total issue valueNew shares ¥522,849,000 / Stock Acquisition Rights ¥3,408,592
Amount of funds to be raisedNew shares ¥522,849,000 / Stock Acquisition Rights ¥343,240,592 (¥3,408,592 from the issuance of the stock acquisition rights and ¥339,832,000 from their exercise) / Estimated net proceeds Not disclosed
Payment date26 March 2026
Intended allotteeName CVI Investments, Inc. / Number of shares 263,400 shares, Name CVI Investments, Inc. / Stock Acquisition Rights 1,712 rights
Exercise price¥1,985 per share. Whether there is an adjustment clause and the adjustment floor: Not disclosed
Exercise period27 March 2026 to 26 September 2029
Number of Stock Acquisition RightsTotal issued: 1,712 rights. Unexercised balance: Not disclosed
Most recent equity financingTiming Offering results under the shelf registration disclosed on 28 November 2025 / Type These common shares / Amount ¥1,891,228,800, Timing Offering results under the shelf registration disclosed on 28 November 2025 / Type Issue price of these stock acquisition rights / Amount ¥12,591,515, Timing Offering results under the shelf registration disclosed on 28 November 2025 / Type Aggregate of the issue price of these stock acquisition rights and the amount payable upon their exercise / Amount ¥1,256,042,515
Items this document does not state (17)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The shelf registration was withdrawn because the payment procedures for the fourth third-party allotment had been completed and all shares and stock acquisition rights under the program had been issued.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for New Shares and Stock Acquisition Rights Issued Through the Fourth Third-Party Allotment Under the Agreement Establishing the Share and Stock Acquisition Rights Issuance Program, and Withdrawal of the Shelf Registration | Renascience Inc. (4889) timely disclosure | Komori